Abstract
A review of the literature concerning the efficacy and safety of combined anti-pseudomonas protected ureidopenicillin piperacillin/tazobactam usage. Randomized clinical trials and their meta-analysis have demonstrated that piperacillin/ tazobactam among non-carbapenem β-lactams is an equally effective alternative to carbapenems in the treatment of severe infections, including those caused by extended-spectrum β-lactamase producing strains, regardless of the infection locus. It can be used in cases of carbapenem de-escalation if it is necessary. The use of this antimicrobial therapy strategy is justified not only from a clinical, but also from an economic point of view.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
